Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.
JSON
Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, Gonzalez G, Garcia-Leon A, Crispie F, O'Connor L, Murphy N, Mossong J, Vergison A, Wienecke-Baldacchino AK, Abdelrahman T, Riccardo F, Stefanelli P, Di Martino A, Bella A, Lo Presti A, Casaca P, Moreno J, Borges V, Isidro J, Ferreira R, Gomes JP, Dotsenko L, Suija H, Epstein J, Sadikova O, Sepp H, Ikonen N, Savolainen-Kopra C, Blomqvist S, Möttönen T, Helve O, Gomes-Dias J, Adlhoch C, COVID study groups
Euro Surveill 26 (16) - [2021-04-00; online 2021-04-24]
We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8).
Category: Genomics & transcriptomics
PubMed 33890566
DOI 10.2807/1560-7917.ES.2021.26.16.2100348
Crossref 10.2807/1560-7917.ES.2021.26.16.2100348